Loading
Life sciences · Journal article
Proceedings of the National Academy of Sciences · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
EZH2 is frequently overexpressed in solid tumors, yet the clinical efficacy of its inhibitors remains limited, highlighting an urgent need to elucidate their cytotoxic mechanisms. Here, we identify EZH2 as a posttranslational suppressor of pyroptosis through direct methylation of GSDMD. We revealed that EZH2 inhibition triggered GSDMD-dependent pyroptosis in prostate cancer cells. Clinical specimens showed an inverse correlation between EZH2 levels and cleaved GSDMD (GSDMD N-terminal, GSDMD-N) levels, reinforcing its role as a negative regulator of GSDMD activation. Mechanistically, EZH2 methylated GSDMD at lysine 168, thereby blocking caspase-1-mediated cleavage and suppressing its activation. Notably, methionine deprivation overcame this blockade and combined with the EZH2 inhibitor GSK126 to enhance pyroptosis and suppress tumor growth in vivo. These findings establish the methionine–EZH2–GSDMD axis as an epigenetic-metabolic hub controlling pyroptosis via posttranslational regulation, providing a mechanistic rationale for co-targeting methionine metabolism and EZH2 in prostate cancer therapy.